Conclusion of the C3 Molecular Testing Program – December 31, 2025

Since our launch in July 2024, the C3 Molecular Testing Program has had a large impact in advancing precision oncology for biliary tract cancer in Canada. In just 18 months, more than 250 patients have undergone molecular testing through this initiative, supported by over 120 clinicians nationwide. We estimate that 40–50%* of completed tests identified a potentially actionable genomic alteration, underscoring the value of molecular testing in expanding clinical options beyond the standard of care.

 

As we reflect on the impact of the program, we are deeply grateful for the engagement and dedication of clinicians across Canada. Your participation has helped patients gain access to targeted therapies and clinical trials, and has contributed valuable data to the C3 Patient Registry, strengthening the national understanding of biliary tract cancer.

​

Although this program is ending, C3 remains committed to supporting both patients and physicians.
 

We will continue to provide:​

• Information on Clinical Trials and how to access Molecular Testing in Canada

• Data collection for our C3 Patient Registry to generate Real World Evidence

• Educational resources for physicians and patients

• Case Presentations through our C3 National BTC Multidisciplinary Rounds 

• Advocacy for molecular testing for biliary tract cancer in Canada